The Predictive Role of Preoperative Pentraxin-3 (PTX3) in Metabolic and Inflammatory Outcomes After Roux-en-Y Gastric Bypass

Istanbul University23 enrolled

Overview

This study evaluated the prognostic value of preoperative pentraxin-3 (PTX3) levels in predicting weight loss, inflammatory resolution (CRP, IL-6), and metabolic improvements (HOMA-IR) following Roux-en-Y gastric bypass in patients with obesity.

This single-center longitudinal study was conducted at Istanbul University Hospital. A total of 23 patients undergoing primary Roux-en-Y gastric bypass were included. PTX3 levels were measured preoperatively, and patients were stratified according to a data-derived cut-off (\~21.7 ng/mL). Outcomes assessed at baseline, 3 months, and 6 months included body weight, BMI, excess weight loss (%EWL), fasting insulin, HOMA-IR, CRP, and IL-6. The primary hypothesis was that preoperative PTX3 would predict postoperative CRP normalization and insulin resistance improvement.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Obesity Metabolic Syndrome Insulin Resistance Inflammation Roux en Y Gastric Bypass Chronic Inflammation

Interventions

Biomarker Stratification by PTX3OTHER

Participants were stratified into groups according to preoperative serum PTX3 levels (≥21.7 ng/mL vs. \<21.7 ng/mL). All participants underwent Roux-en-Y gastric bypass and were prospectively evaluated for metabolic (HOMA-IR, %EWL) and inflammatory (CRP, IL-6) outcomes during 6 months of follow-up.

Eligibility

Sex: ALLMin age: 18 DaysMax age: 65 Days

Medical Language ↔ Plain English

Inclusion Criteria: * Age: 18-65 years * Body mass index (BMI) ≥40 kg/m², or BMI ≥35 kg/m² with obesity-related comorbidity * Eligible for primary Roux-en-Y gastric bypass * Able to provide written informed consent Exclusion Criteria: * Previous bariatric surgery * Severe hepatic, renal, or cardiac failure * Active infection or inflammatory disease * Malignancy

Outcomes

Primary Outcomes

Change in HOMA-IR from baseline to 6 months

Assessment of the improvement in insulin resistance after Roux-en-Y gastric bypass, measured by the homeostasis model assessment of insulin resistance (HOMA-IR). Preoperative PTX3 stratification will be used to evaluate predictive value.

Time frame: Baseline, 3 months, 6 months

Secondary Outcomes

Percent Excess Weight Loss (%EWL) at 6 months

Evaluation of weight loss outcomes after surgery, calculated as percent excess weight loss (%EWL). Comparisons will be made between PTX3 high vs. low groups.

Time frame: 6 months

CRP normalization at 6 months

Proportion of patients achieving CRP ≤5 mg/L after surgery. Predictive value of baseline PTX3 will be assessed.

Time frame: 6 months

Change in IL-6 from baseline to 6 months

Change in serum IL-6 levels after surgery, analyzed between PTX3 high vs. low groups.

Time frame: Baseline, 3 months, 6 months